CircuLite has announced that its Synergy Circulatory Support System will be included in four presentations at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (Miami, USA, 22–26 October). CircuLite recently announced CE marking approval for the Synergy System, which is a micro-pump designed to halt the progression of heart failure and to improve symptoms and exercise tolerance.
By working with the heart’s native pumping capacity, the Synergy System is specifically targeted for treatment of ambulatory heart failure patients (INTERMACS 4,5,6 / NYHA III and early IV) who remain symptomatic despite standard medical management.
Synergy will be discussed in the following presentations:
- Daniel Burkhoff, adjunct associate professor at Columbia University and CircuLite’s chief medical officer, will present “CircuLite for patients with INTERMACS 4, 5, and 6” during Session III, ‘Progress with ventricular assist devices’, in the ‘Interventional Heart Failure’ symposia on Tuesday, 23 October.
- Burkhoff will present “State of the field keynote: future perspectives in the device-based treatment for heart failure” during Session IV, ‘Interventional Heart Failure,’ in the ‘First-in-Human Studies: Global Regulatory and Translational Considerations symposia’ on Tuesday, 23 October.
- Juan F Granada, executive director and chief scientific officer at the Skirball Center for Cardiovascular Research (CRF Skirball Research Center) will present “Preclinical review: Experimental models and biological considerations for the validation of heart failure devices” during Session IV, ‘Interventional Heart Failure,’ in the ‘First-in-Human Studies: Global Regulatory and Translational Considerations’ symposia on Tuesday, 23 October.
- Burkhoff will also present “Novel device-based therapies for advanced heart failure” during Plenary Session XIV, ‘TCT 2012 Game-Changing Therapies II. Is Interventional Heart Failure the Next Big Breakthrough?’ on Thursday, 25 October.
Synergy is an investigational device in the United States.